Guidance, NICE advice and quality standards In development

Skip to filtersSkip to results

Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 2 selected

Guidance programme

Showing 26 to 50 of 302

TitleTypeExpected publication date
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]Technology appraisal guidanceTBC
Baricitinib for treating juvenile idiopathic arthritis in children and young people aged 1 to 17 [ID6143]Technology appraisal guidanceTBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]Technology appraisal guidanceTBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]Technology appraisal guidanceTBC
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212Technology appraisal guidance
Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211Technology appraisal guidanceTBC
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]Technology appraisal guidanceTBC
Belzutifan for treating tumours associated with von Hippel-Lindau disease [ID3932]Technology appraisal guidanceTBC
Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]Technology appraisal guidanceTBC
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]Technology appraisal guidance
Bimatoprost implant for treating open angle glaucoma or ocular hypertension in people who are unsuitable for topical treatments [ID6180]Technology appraisal guidanceTBC
Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]Technology appraisal guidance
Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]Technology appraisal guidanceTBC
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]Technology appraisal guidance
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]Technology appraisal guidanceTBC
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]Technology appraisal guidanceTBC
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]Technology appraisal guidance
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]Technology appraisal guidance
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]Technology appraisal guidanceTBC
Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]Technology appraisal guidanceTBC
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment ID6370Technology appraisal guidanceTBC
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]Technology appraisal guidanceTBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]Technology appraisal guidanceTBC
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]Technology appraisal guidance
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All